ABBV
AbbVie Inc.
ABBV's fundamentals are strong: its operating margin rose 17 points to 32% and it turned 29% of its revenue into free cash flow. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ABBV Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Stable |
ABBV's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ABBV PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $294 | — |
| Cheap | 21x | $121 | -59% |
| Fair | 38x | $220 | -25% |
| Current | 51x | $294 | — |
| Expensive | 81x | $473 | +61% |
Historical ranges are pointers, not guarantees.
ABBV's PE is 51x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ABBV Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
ABBV has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ABBV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $15.81 | +172% |
| Q3 2026 | $5.81 | +340% |
| Q2 2026 | $3.54 | +69% |
| Q1 2026 | $2.03 | -14% |
| Q4 2025 | $2.36 | -1.7% |
| Q3 2025 | $1.32 | -54% |
| Q2 2025 | $2.10 | -30% |
| Q1 2025 | $2.35 | -30% |
| Q4 2024 | $2.40 | -12% |
ABBV has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ABBV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $17.4B | +10% |
| Q2 2026 | $17B | +10% |
| Q1 2026 | $15B | +12% |
| Q4 2025 | $16.6B | +10% |
| Q3 2025 | $15.8B | +9.1% |
| Q2 2025 | $15.4B | +6.6% |
| Q1 2025 | $13.3B | +8.4% |
| Q4 2024 | $15.1B | +5.6% |
ABBV's revenue has grown year over year for 11 quarters in a row: $17.4B last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 36% | +24 points |
| Q2 2026 | 38% | +6.1 points |
| Q1 2026 | 27% | -1.4 points |
| Q4 2025 | 27% | +37 points |
| Q3 2025 | 12% | -14 points |
| Q2 2025 | 32% | +4.1 points |
| Q1 2025 | 28% | +5.3 points |
| Q4 2024 | -9.9% | -32 points |
ABBV has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ABBV on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ABBV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $7.3B | +10% |
| Q2 2026 | $3.1B | -36% |
| Q1 2026 | $3.6B | +155% |
| Q4 2025 | $4.9B | -28% |
| Q3 2025 | $6.6B | +28% |
| Q2 2025 | $4.9B | +141% |
| Q1 2025 | $1.4B | -64% |
| Q4 2024 | $6.8B | +49% |
ABBV's free cash flow has been positive every quarter for seven years: $18.9B over the past year, down 4.1% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ABBV on cash flow, with more consistent year-over-year improvement.
ABBV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +1M shares |
| 1 year | 0% | -- |
| 3 years | +0.1% | +1M shares |
| 5 years | -0.3% | -5M shares |
| Available history | +19% | +288M shares |
ABBV has 1.8B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5M |
| Q2 2026 | $9M |
| Q1 2026 | $1.5B |
| Q4 2025 | $3M |
| Q3 2025 | $4M |
| Q2 2025 | $12M |
| Q1 2025 | $961M |
| Q4 2024 | $358M |
ABBV spent $1.5B buying back its own shares over the past year, up 13% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ABBV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ABBV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.4x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 2.7x | Moderate |
| Q3 2025 | 3.6x | Elevated |
| Q2 2025 | 3.3x | Elevated |
| Q1 2025 | 3.5x | Elevated |
| Q4 2024 | 3.5x | Elevated |
ABBV's net debt is about 2.4 years of its operating earnings (EBITDA), down from 3.6 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ABBV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.4 | Overbought |
| Stochastic | 86.7 | Overbought |
ABBV's weekly RSI is 71 (overbought) and its Stochastic is 87 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ABBV PE vs Healthcare Sector
| Metric | ABBV | Sector median | Relative |
|---|---|---|---|
| PE | 51x | 26x | 96% above |
| PE % | 64 | 29 | 35 pts above |
ABBV is trading at 51x earnings, a 96% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ABBV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $281.9 | 4.4% above |
| 20 week MA | $266.1 | 11% above |
| 50 week MA | $238.2 | 24% above |
| 100 week MA | $219.0 | 34% above |
| 200 week MA | $190.8 | 54% above |
ABBV has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ABBV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $89.2 | $103.3 | +16% |
| 2021 | $103.3 | $133.1 | +29% |
| 2022 | $133.1 | $163.1 | +23% |
| 2023 | $163.1 | $155.0 | -5% |
| 2024 | $155.0 | $178.0 | +15% |
| 2025 | $178.0 | $230.0 | +29% |
| 2026 YTD | $230.0 | $294.5 | +28% |
ABBV has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.